TY - JOUR T1 - Randomized controlled trial of gut decontamination in pediatric patients undergoing allogeneic hematopoietic cell transplantation JF - medRxiv DO - 10.1101/2021.12.16.21267940 SP - 2021.12.16.21267940 AU - Christopher J. Severyn AU - Benjamin A. Siranosian AU - Sandra Tian-Jiao Kong AU - Angel Moreno AU - Michelle M. Li AU - Nan Chen AU - Christine N. Duncan AU - Steven P. Margossian AU - Leslie E. Lehmann AU - Shan Sun AU - Tessa M. Andermann AU - Olga Birbrayer AU - Sophie Silverstein AU - Soomin Kim AU - Niaz Banaei AU - Jerome Ritz AU - Anthony A. Fodor AU - Wendy B. London AU - Ami S. Bhatt AU - Jennifer S. Whangbo Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/17/2021.12.16.21267940.abstract N2 - Background Gut decontamination (GD) can decrease the incidence and severity of acute graft- versus-host-disease (aGVHD) in murine models of allogeneic hematopoietic cell transplantation (HCT). Several HCT centers standardly practice GD with different antibiotic regimens. In this pilot study, we examined the impact of GD on the gut microbiome composition and incidence of aGVHD in HCT patients.Methods We randomized 20 pediatric patients undergoing allogeneic HCT to receive (GD) or not receive (no-GD) oral vancomycin-polymyxin B from day -5 through neutrophil engraftment. We evaluated shotgun metagenomic sequencing of serial stool samples to compare the composition and diversity of the gut microbiome between study arms. We assessed clinical outcomes in the 2 arms and performed strain-specific analyses of pathogens that caused bloodstream infections (BSI).Results The two arms did not differ in Shannon diversity of the gut microbiota at two weeks post- HCT (Genus, p=0.8; Species, p=0.44) or aGVHD incidence (p=0.58). Immune reconstitution of T- cell subsets was similar, but absolute CD19+ B-cell counts were higher in the GD arm at 12 months post-HCT (p=0.02). Five patients in the no-GD arm had eight BSI episodes vs one episode in the GD arm (p=0.09). The BSI-causing pathogens were traceable to the gut in seven of eight BSI episodes in the no-GD arm, including the genus Staphylococcus.Conclusions While GD did not differentially impact Shannon diversity or clinical outcomes, our findings suggest that GD may protect against gut-derived BSI in HCT patients by decreasing the prevalence or abundance of gut microbial pathogens.Key points:– In this phase 2 randomized study of gut decontamination (GD) in 20 pediatric HCT patients, neither two-week post-HCT Shannon diversity of the gut microbiome nor incidence of aGVHD differ between the GD and no-GD arms.– All bloodstream infections (BSIs) caused by pathogens traceable to the gut either temporally or via strain-specific analysis (concomitant gut colonization) occurred in patients in the no-GD arm; this suggests that GD with vancomycin-polymyxin B may decrease the incidence of gut-derived BSI in allo-HCT patients.– In contrast to prior studies, we find that non-mucosal barrier injury (MBI) pathogens, such as Staphylococcus aureus, can be found in the gut microbiome of HCT patients.Competing Interest StatementExcept for those listed below, the authors have declared that no potential conflict of interest exist. B. Siranosian: Employee: Cellular Longevity Inc. Consultant: Imago Biosciences. S. Margossian: Consultant: Novartis Salary: CueBio Inc J. Ritz: Consultant: Akron Biotech, Avrobio, Clade Therapeutics, Garuda Therapeutis, LifeVault Bio, Novartis, Rheos Medicines, Talaris Therapeutics, TScan Therapeutics. Research funding: Amgen, Equillium, Kite/Gilead, Novartis A. Fodor: Consultant: Gelesis, ByHeart and L-nutra W. London: Consultant: Jubilant Draximage and Merck A. Bhatt: Scientific Advisory board: ArcBio, Caribou Biosciences Consultant: Kaleido Biosciences, biomX Research collaboration without funding support: 10x Genomics, Illumina, Oxford Nanopore Technologies Nonprofit Board: Global Oncology, Inc. J. Whangbo: Employee: Vor BiopharmaClinical TrialNCT02641236Funding StatementThis work utilized computing resources provided by the Stanford Genetics Bioinformatics Service Center, supported by NIH S10 Instrumentation Grant S100D023452. Computing costs were supported via a NIH S10 Shared Instrumentation Grant 1S10OD02014101. C.J.S. is a Pete and Arline Harman Fellow with the Stanford Maternal & Child Health Research Institute (MCHRI) and supported by the MCHRI and T32-DK098132. A.S.B. is supported by Damon Runyon Clinical Investigator Award, V Foundation Scholar award, Sloan Foundation Fellowship, Emerson Collective grant, NIH R01 AI143757 and R01 AI148623. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the institutional review board (IRB) under the IRB of Dana-Farber Cancer Institute (DFCI) (Protocol #15-394 approved Oct. 2015; principal investigator: J.S.W.), was performed at Boston Childrens Hospital (BCH) and DFCI. IRB protocol was open to patient entry March 2016 through September 2019. Informed consent for the patient (if <18 years), parent (if <18 years), or legally authorized representative, was obtained prior to any specimen collection. Full protocol available at DFCI. Trial is registered under ClinicalTrials.gov Identifier: NCT02641236.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. All sequencing data sets from the current study will be deposited in the Sequence Read Archive under the National Center for Biotechnology Information (NCBI) BioProject ID PRJNA787952 at http://www.ncbi.nlm.nih.gov/bioproject/787952 (data release will occur at time of publication) http://www.ncbi.nlm.nih.gov/bioproject/787952 ER -